Nav: Home

Drug companies' sexually explicit ads reaching too many youngsters

July 11, 2019

Virtually every day, millions of children and adolescents are being bombarded by sexually explicit direct-to-consumer advertising, despite pharmaceutical CEOs' claims to the contrary.

Leading business ethicist Denis Arnold from the University of North Carolina at Charlotte co-authored the study, "Self-Regulation in the Pharmaceutical Industry: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials," published in the just released Journal of Health Politics, Policy and Law. Jim Oakley, professor and chair of marketing at Lewis University, is the study co-author.

Arnold, the Surtman Distinguished Professor of Business Ethics in the Belk College of Business, and Oakley studied marketing campaigns for erectile dysfunction (ED) drugs during a six-year period. These products include sildenafil citrate, manufactured and marketed as Viagra in the United States by Pfizer; and tadalafil, manufactured and marketed as Cialis in the United States by Eli Lilly.

"PhRMA Guiding Principles," for which both companies have certified their compliance, state that 90 percent of the audience viewing sexually explicit advertisements must be 18 or older. These principles, developed by the Pharmaceutical Research and Manufacturers of America trade organization (PhRMA), were first introduced in 2005, and under these guidelines, a company must commit to internal processes to ensure compliance with the principles, complete an annual certification of compliance and submit a document to PhRMA signed by the CEO and chief compliance officer attesting to compliance.

"Pfizer and Eli Lily have never met the standard, and public disclosure of this misconduct in 2013 did not alter their behavior," stated Arnold, past president of the Society for Business Ethics. "The most reasonable explanations for this misconduct are that a public commitment to the standard helps block additional regulation, while at the same time there are no penalties for routinely violating the standard.

"Firms continued to aggressively advertise ED drugs when they knew children and adolescents would be exposed to these sexually explicit ads billions of times," Arnold added.

In 2013, Arnold and Oakley published a research article also in the Journal of Health Politics, Policy and Law that found firms never met the industry standard during a different four-year period they analyzed. This study was widely publicized and acknowledged by the manufacturers of ED drugs and PhRMA. In this new study, Arnold and Oakley sought to answer this question, "Would public disclosure of non-compliance with industry standards improve firm behavior?" The answer, as determined by their recent study, is "no." Eric Patashnik, editor-in-chief of the Journal of Health Politics, Policy and Law and the Julis-Rabinowitz Professor of Public Policy and Professor of Political Science at Brown University, stated,

"Broadly, they [Arnold and Oakley] found that public disclosure did not cause firms to alter their behavior, suggesting that the pharmaceutical industry is simply not willing to police itself."

Other findings from "Self-Regulation in the Pharmaceutical Industry: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials" include:
  • Twenty years after its introduction in the U.S., spending on direct-to-consumer advertising rose to $6.083 billion or five times as much as 1996 in inflation-adjusted dollars. This is more than double what the U.S. film industry spent on marketing

  • On average, there were 35-40,000 ED advertising impressions on children and adolescents daily, totaling more than five billion impressions, between Jan. 1, 2010, and Dec. 31, 2015

  • Public disclosure of non-compliance with self-regulatory direct-to-consumer advertising standards did not bring advertising into compliance. Results demonstrate that firms failed to meet the industry standard during every quarter of this study's six-year period

  • Results support previous research that demonstrated that pharmaceutical self-regulation is a deceptive blocking strategy aimed at preventing further regulation rather than a means for the industry to police itself
-end-


University of North Carolina at Charlotte

Related Erectile Dysfunction Articles:

Erectile dysfunction medicines do not cause melanoma, analysis of large studies finds
Use of the erectile dysfunction drug Viagra does not cause the development of melanoma, a deadly form of skin cancer.
Erectile dysfunction drugs are safe, possibly beneficial after heart attack
Men who filled prescriptions for erectile dysfunction drugs in the years following a heart attack had a substantially lower risk of dying or being hospitalized for heart failure than men who did not use these drugs, according to a study scheduled for presentation at the American College of Cardiology's 66th Annual Scientific Session.
Hair loss and prostate drug linked to persistent erectile dysfunction in men
Men with longer exposure to the drugs finasteride and dutasteride had a higher risk of getting persistent erectile dysfunction than men with less exposure, reports a new study.
No link found between erectile dysfunction drugs and risk of prostate cancer
While some previous studies have indicated that taking erectile dysfunction drugs may reduce the likelihood of developing prostate cancer, new research published in The Journal of Urology found that these drugs do not play a role in preventing prostate cancer.
Taking PDE5 inhibitors for erectile dysfunction unlikely to increase risk of skin cancer
Three drugs widely prescribed for erectile dysfunction are unlikely to increase risk of malignant melanoma, according to a study published in the journal PLOS Medicine.
Blueberries, citrus fruits and red wine associated with reduced erectile dysfunction
Flavonoid-rich foods are associated with a reduced risk of erectile dysfunction -- according to a new collaborative study from the University of East Anglia and Harvard University.
Most men with erectile dysfunction are satisfied with penile prostheses
Most men who receive penile prostheses are very satisfied with the implants, indicating that the intervention is a valid treatment for erectile dysfunction.
Vanderbilt study finds erectile dysfunction drug may benefit patients at risk for diabetes
The drug sildenafil, sold as Viagra and other brand names, improves insulin sensitivity in people at risk for diabetes, researchers at Vanderbilt University Medical Center reported today.
Low quality of life and depression may contribute to erectile dysfunction in men with sleep apnea
Burdens related to poor sleep may put men with sleep apnea at increased risk of erectile dysfunction.
Study examines US trends in the use of penile prostheses to treat erectile dysfunction
US researchers have published the first large population-based study of nationwide trends in erectile dysfunction and its surgical management from 2001 to 2010.

Related Erectile Dysfunction Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".